A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.
Drug Short Name
MOAB HER2; rhuMAb HER2
anti-c-erB-2; anti-c-erbB2 monoclonal antibody; anti-ERB-2; anti-erbB-2; anti-erbB2 monoclonal antibody; anti-HER2/c-erbB2 monoclonal antibody; anti-p185-HER2; MOAB HER2; monoclonal antibody c-erb-2; monoclonal antibody HER2
US Brand Names